Septerna - 1781718 - SEPTERNA INC
Financial Performance:
- No specific revenue, earnings, cash flow, or debt figures disclosed; company is pre-revenue and in clinical development phases.
- No mention of profit margins or deferred revenue; focus is on operational milestones and pipeline progress.
Guidance and Future Outlook:
- SCP-479 (Hyperparathyroidism): Phase 1 trial data anticipated in Q1 2027; target PTH reduction of ~50% and calcium increase of 0.5–1.0 mg/dL.
- SCP-204 (Graves' Disease/Thyroid Eye Disease): Phase 1 initiation expected Q1 2027; healthy volunteer data expected by end of 2027.
- SCP-631 (Mast Cell/X2): Currently between Phase 1 and Phase 2; planning signal-finding studies for new indications (e.g., migraine) rather than large Phase 3 immediately.
- Novo Partnership: Five targets in collaboration; first development candidate selected and moving forward (announced last quarter).
- Timeline: Aims to commence Phase 2 for SCP-479 in the second half of 2026, contingent on chronic toxicology studies and Phase 1 completion.
Business Segments and Product Lines:
- SCP-479: Oral small molecule targeting PTH1R; designed to mimic peptide function with a 3–4 day half-life for once-daily dosing.
- SCP-204: Oral small molecule targeting TSHR for Graves' disease and thyroid eye disease; selective against FSH/LH receptors; completed GLP toxicology (on-target hypothyroidism observed).
- SCP-631: Negative allosteric modulator of MRG-PERX-2 (mast cell); completed Phase 1; unique mechanism blocks all endogenous agonists with ~99% occupancy and slow off-rate.
- Pipeline: Includes a second PTH agonist program for osteoporosis (short-acting) and earlier-stage programs.
- Platform: "Native Complex Platform" enables discovery of oral small molecules for difficult GPCR targets by identifying distinct binding pockets.
Market and Competitive Landscape:
- Hyperparathyroidism: ~70,000–80,000 patients in the US; current standard of care involves calcium/vitamin D or daily injections (Ascendis' Yorvipath).
- Competitive Differentiation: SEP-TURNA is the only oral PTH receptor small molecule in development; competitor "Encallerate" targets a different mechanism (calcium-sensing receptor) and requires intact parathyroid tissue, limiting its utility for post-surgical patients.
- Graves' Disease: Unmet need in relapse management and thyroid eye disease; current treatments lack novelty; SCP-204 addresses both disease states via TSHR blockade.
- Mast Cell Disease: Original CSU program failed; pivoting to migraine and other indications with emerging data linking mast cells to pathology.
Risks and Challenges:
- Clinical Execution: Reliance on healthy volunteer data to predict efficacy in patients with absent parathyroid glands (proof-of-concept risk).
- Regulatory/Timing: Delays in toxicology studies could push Phase 2 back; Phase 3 endpoints for Encallerate may impact competitive positioning.
- Mechanism Risk: Osteoporosis program requires a distinct short-acting compound vs. the long-acting hyperparathyroidism molecule.
- Market Adoption: Potential pricing pressure; need to demonstrate clear patient benefit over injectables to justify oral formulation adoption.
Management Commentary and Tone:
- Tone: Confident and optimistic regarding the "Native Complex Platform" capabilities, particularly overcoming historical challenges in oral GPCR drug discovery.
- Strategy: Emphasis on expanding the treatable patient population via oral formulations; management views SCP-479 as a direct PTH replacement rather than a symptomatic treatment.
- Differentiation: Strong belief in the mechanistic superiority of full PTH replacement (SCP-479) over calcium-sensing receptor modulators for post-surgical patients.
Analyst Questions and Answers:
- Q: Is Phase 1 in healthy volunteers sufficient? A: Yes; receptor biology is identical, and all prior successful peptides followed this path.
- Q: What is the unmet need? A: Daily injections are burdensome for patients treated for decades; oral therapy targets moderate patients and those avoiding injections.
- Q: Why is oral PTH discovery difficult? A: Historically difficult to mimic peptide binding with small molecules; SEP-TURNA claims to be the only successful small molecule approach.
- Q: How does SCP-479 compare to Encallerate? A: Encallerate is mechanistically different (requires intact glands) and targets a different endpoint; SCP-479 offers direct hormone replacement.
- Q: How will titration work? A: Will follow precedents from injectable peptides (titrating drug up while reducing calcium/Vit D supplements).
- Q: Why pivot mast cell indications? A: To find signal in smaller, focused studies (e.g., migraine challenge) before committing to large Phase 2 trials.
Other Key Points:
- Osteoporosis Program: Distinct from hyperparathyroidism program; requires short-acting compound to promote bone formation (anabolic effect) vs. long-acting for calcium stability.
- SCP-204 Data: Preclinical data showed normalization of thyroid hormones and reversal of thyroid histology/orbital proptosis in mouse models of Graves' disease.
- Novo Collaboration: Partnership established mid-2025 for five targets; first candidate selected recently.
- Safety Profiles: SCP-631 showed safety in Phase 1; SCP-204 showed expected on-target hypothyroidism in tox studies, which is manageable clinically.
- Company
- SEPTERNA INC
- Keywords
- SEPTERNA INC